Comparing the Efficacy and Safety of Conventional Therapy With Conventional Therapy Combined Esketamine in the Treatment of Fibromyalgia: A Multicenter Clinical Study
Fibromyalgia is a chronic pain syndrome where current medications have limited efficacy and a slow onset of action. Esketamine shows potential as a rapid-acting analgesic, but previous low-dose studies failed to demonstrate long-term benefits. The efficacy of higher-dose ESK as an adjunctive therapy when standard treatments are insufficient remains unclear.
• Diagnosed with FM as defined by the ACR FM diagnostic criteria;26
• Patients between ages 18-65 years with proper cognitive function and language skills for the study;
• Patients newly diagnosed with FM as defined by the ACR FM diagnostic criteria26 or those currently receiving venlafaxine and pregabalin for over two weeks with inadequate symptom relief requiring dose escalation;
• A score of ≥4 on the average pain item of the BPI 18 for at least 3 months.